Evidence map›Paper›PMID 38863047›Full record

ReviewActas espanolas de psiquiatria2024

Is EEG Entropy a Useful Measure for Alzheimer's Disease?

Manuel A Zúñiga, Ángela Acero-González, Juan C Restrepo-Castro, Miguel Ángel Uribe-Laverde, Daniel A Botero-Rosas, Borja I Ferreras, María C Molina-Borda, María Paula Villa-Reyes

Abstract readReview
In one paragraph

Review in Actas espanolas de psiquiatria, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manuel A ZúñigaFacultad de Medicina, Universidad Nacional de Colombia,111321 Bogotá, Colombia.
Ángela Acero-GonzálezFacultad de Medicina, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
Juan C Restrepo-CastroFacultad de Psicología, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
Miguel Ángel Uribe-LaverdeFacultad de Ingeniería, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
Daniel A Botero-RosasFacultad de Medicina, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
Borja I FerrerasFacultad de Medicina, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
María C Molina-BordaFacultad de Medicina, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.
María Paula Villa-ReyesFacultad de Medicina, Universidad de La Sabana, 250001 Chía, Cundinamarca, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of individuals diagnosed with Alzheimer's disease (AD) has increased, and it is estimated to continue rising in the coming years. The diagnosis of this disease is challenging due to variations in onset and course, its diverse clinical manifestations, and the indications for measuring deposit biomarkers. Hence, there is a need to develop more precise and less invasive diagnostic tools. Multiple studies have considered using electroencephalography (EEG) entropy measures as an indicator of the onset and course of AD. Entropy is deemed suitable as a potential indicator based on the discovery that variations in its complexity can be associated with specific pathologies such as AD. METHODOLOGY: Following PRISMA guidelines, a literature search was conducted in 4 scientific databases, and 40 articles were analyzed after discarding and filtering.

resultsThere is a diversity in entropy measures; however, Sample Entropy (SampEn) and Multiscale Entropy (MSE) are the most widely used (21/40). In general, it is found that when comparing patients with controls, patients exhibit lower entropy (20/40) in various areas. Findings of correlation with the level of cognitive decline are less consistent, and with neuropsychiatric symptoms (2/40) or treatment response less explored (2/40), although most studies show lower entropy with greater severity. Machine learning-based studies show good discrimination capacity.

conclusionsThere is significant difficulty in comparing multiple studies due to their heterogeneity; however, changes in Multiscale Entropy (MSE) scales or a decrease in entropy levels are considered useful for determining the presence of AD and measuring its severity.

Indexed as

Alzheimer DiseaseElectroencephalographyEntropyHumans

Identifiers

PMID38863047
PMCPMC11194159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.